For example an ongoing phase 1 study (NCT02632708) of patients with IDH1 or IDH2 mutated AML receive ivosidenib (for IDH1 mutated) or enasidenib (for IDH2 mutated) combined with standard therapy for newly diagnosed AML and can continue ivosidenib or enasidenib maintenance until relapse, unacceptable toxicity, or alloSCT. Here, IDH2 is linked to acute myeloid leukemia.